JAMA Network
About The Study: Among patients with alcohol use disorder (AUD) and comorbid obesity/type 2 diabetes, the use of semaglutide and liraglutide were associated with a substantially decreased risk of hospitalization due to AUD. This risk was lower than that of officially approved AUD medications. Semaglutide and liraglutide may be effective in the treatment of AUD, and clinical trials are urgently needed to confirm these findings.
Corresponding Author: To contact the corresponding author, Markku Lähteenvuo, MD, PhD, email [email protected].
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(10.1001/jamapsychiatry.2024.3599)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
